Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

Women hospital staff working night shifts may face increased risk of heart disease

Women hospital staff working night shifts may be compromising their own health as they try to improve the health of patients, Dr. Joan Tranmer told the Canadian Cardiovascular Congress 2011, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

24 Oct 2011

Inhibition of miR-33a/b suppresses triglyceride levels, increases HDL-C cholesterol

Researchers at NYU Langone Medical Center today announce findings published in the October 20 issue of Nature that show for the first time the inhibition of both microRNA-33a and microRNA-33b (miR-33a/b) with chemically modified anti-miR oligonucleotides markedly suppress triglyceride levels and cause a sustained increase in high density lipoprotein cholesterol (HDL-C) "good" cholesterol.

21 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.

7 Oct 2011

Increasing levels of 'good' cholesterol reduces risk for heart attack and stroke among diabetics

Increasing levels of high-density lipoproteins, better known as HDL or "good" cholesterol, reduced the risk for heart attack and stroke among patients with diabetes. That's according to a new study appearing online today in The American Journal of Cardiology.

7 Oct 2011

Valeant's colesevelam New Drug Submission for hypercholesterolemia receives Canadian approval

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Valeant International (Barbados) SRL, has received notice that the New Drug Submission for colesevelam hydrochloride (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, has been approved by the Canadian regulatory authority Health Canada.

28 Sep 2011

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.

27 Sep 2011

Six ways to prevent coronary artery disease

In honor of National Cholesterol Education Month, Hotze Health & Wellness Center (HHWC) is encouraging both men and women to take a proactive role in healthy aging, specifically heart disease prevention. HHWC is advocating effective measures to prevent heart attacks and is shedding new light on cholesterol myths and the dangers of cholesterol-lowering (statin) drugs.

23 Sep 2011

JCPT publishes 'The Need for Increased Utilization of Statins After Occlusive Stroke' study

Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published a clinical study in the current issue of the Journal of Cardiovascular Pharmacology and Therapeutics (JCPT) titled "The Need for Increased Utilization of Statins After Occlusive Stroke."

15 Sep 2011

Researchers use MRI and PET/CT to assess safety, efficacy of heart drug dalcetrapib

Researchers from Mount Sinai School of Medicine have for the first time used several imaging techniques to prove the efficacy of a promising new treatment for atherosclerosis—the build-up of plaque in artery walls that can lead to a heart attack.

13 Sep 2011

Aggressive medical management better than stenting for prevention of recurrent stroke

Patients at a high risk for a second stroke who received intensive medical treatment had fewer strokes and deaths than patients who received a brain stent in addition to the medical treatment, a large nationwide clinical trial has shown. The investigators published the results in today's online first edition of the New England Journal of Medicine.

8 Sep 2011

Intensive medical treatment more effective in preventing second stroke than stenting

People who received intensive medical treatment following a first stroke had fewer second episodes and were less likely to die than people who received brain stents in addition to medical treatment, according to a new report in the New England Journal of Medicine, to be published online Sept. 7.

8 Sep 2011

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

AMT, NIH enter exclusive license agreement for use of AAV5-based gene therapy vectors

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.

6 Sep 2011

Dr. Reddy’s initiates DRL-17822 Phase II study in type II dyslipidemia

Dr. Reddy's Laboratories announced the initiation of dosing with DRL-17822 in patients with diagnosis of type II dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.

2 Sep 2011

Researchers demonstrate benefits of 8-week 'Beating Heart Problems' group programme

Researchers from the Heart Research Centre in Melbourne, Australia, have demonstrated the benefits of the 8-week 'Beating Heart Problems' group programme in a randomised controlled trial.

30 Aug 2011

EAS/ESC develops new dyslipidaemias guidelines

Clinicians should aim for comprehensive lipid control using lifestyle as a first step and tailoring treatment to patients. Lifestyle interventions, including stopping smoking, improving diet, exercising sufficiently and moderate alcohol consumption, should be the crucial first step for managing lipids in all patients.

29 Aug 2011

Lipoprotein News and Research

Further Reading